CORP: Practical tools for improving experimental design and reporting of laboratory studies of cardiovascular physiology and metabolism by Weeks, KL et al.
 1
CORP: Practical Tools for Improving Experimental Design and Reporting of Laboratory 1 
Studies of Cardiovascular Physiology and Metabolism 2 
Kate L. Weeks1, 2, Darren C. Henstridge1, Agus Salim1,3, Jonathan E. Shaw1, Thomas H. Marwick1, 3 
Julie R. McMullen1,2 4 
1 Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia 5 
2 Department of Diabetes, Central Clinical School, Monash University, Clayton, VIC 3800, Australia 6 
3 Department of Mathematics and Statistics, PS2 Building, La Trobe University VIC 3086, Australia 7 
 8 
 9 
Running Head: Experimental design: Survey, training & practical tools 10 
 11 
 12 
Address for Correspondence:  13 
Julie R. McMullen 14 
Baker Heart and Diabetes Institute 15 
Melbourne, VIC 3004 16 
Australia 17 
Tel: +61 (0) 3 8532 1194 18 
Email: julie.mcmullen@baker.edu.au 19 
 20 
 21 
  22 
 2
Abstract 23 
An exercise was undertaken to improve the quality of animal cardiac and metabolic studies at the 24 
Baker Heart and Diabetes Institute, Australia. The exercise consisted of: i) a short survey to 25 
acquire baseline data on current practices regarding the conduct of animal studies; ii) a series of 26 
presentations for promoting awareness, and providing advice and practical tools for improving 27 
experimental design; iii) a follow-up survey 12 months later to assess whether practices had 28 
changed. The surveys were compulsory for responsible investigators (N=16; paired data 29 
presented).  Other investigators named on animal ethics applications were encouraged to 30 
participate (2017-total of 36 investigators; 2018-37 investigators). The major findings to come from 31 
the exercise included: 1) a willingness of investigators to make changes when provided with 32 
knowledge/tools and solutions which were relatively simple to implement (e.g. proportion of 33 
responsible investigators showing improved practices using a structured method for randomization 34 
was 0.44, 95% CI (0.19; 0.70), P=0.003, and de-identifying drugs/interventions was 0.40, 95% CI 35 
(0.12; 0.68), P=0.010); 2) resistance to change if this involved more personnel and time (e.g. as 36 
required for allocation concealment); and 3) evidence that changes to long term practices (“habits”) 37 
require time and follow-up. Improved practices could be verified based on changes in reporting 38 
within publications, or documented evidence provided during laboratory visits.  In summary, this 39 
exercise resulted in changed attitudes, practices, and reporting but continued follow-up, 40 
monitoring, and incentives are required. Efforts to improve experimental rigor will reduce bias and 41 
will lead to findings with the greatest translational potential.  42 
 43 
Keywords: Experimental design, preclinical, randomization, allocation concealment, blinding 44 
New & Noteworthy 45 
The goal of this exercise was to encourage preclinical researchers to improve the quality of their 46 
cardiac and metabolic animal studies by: i) increasing awareness of concerns which can arise from 47 
sub-optimal experimental designs, ii) providing knowledge, tools and templates to overcome bias, 48 
and iii) conducting two short surveys over 12 months to monitor change. Improved practices were 49 
identified for the uptake of structured methods for randomization, and de-identifying 50 
interventions/drugs.   51 
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Introduction 52 
Over the last decade there have been increasing concerns around the reproducibility of preclinical 53 
animal research and the lack of detail provided in publications in relation to experimental design (7-54 
9, 29, 48).  Leaders in the field have highlighted that there is a natural tendency for scientists to 55 
“see” results and report data in a manner that confirms their original hypothesis, and that failure to 56 
control for bias, and rationalizing behaviors such as P-hacking, can lead to results and conclusions 57 
which are less likely to be replicated (19, 35, 42, 45). The ARRIVE guidelines (Animal Research: 58 
Reporting In Vivo Experiments) have been developed to encourage improvements in experimental 59 
design and reporting (28).  However, while these guidelines have received endorsement from 60 
numerous journals, universities, research institutes and funding agencies, there has been concern 61 
that the guidelines have not been adequately implemented in practice (6). This is not helped by a 62 
system in which individuals are judged on the numbers of publications with novel and positive 63 
results published in high impact factor journals rather than on the number and quality of 64 
publications with robust experimental design (44). 65 
Investigators undertaking animal research are not typically provided with formal training in regard 66 
to experimental design. Furthermore, until relatively recently, there have been few mandatory 67 
requirements for reporting details such as methods used for randomization, allocation 68 
concealment, and blinding. It is now well recognised that studies without formal procedures for 69 
limiting bias have a high potential of leading to results and conclusions that are exaggerated (7-9, 70 
29, 48), particularly those claiming that a particular drug/intervention provided significant benefit in 71 
a disease animal model (36).  72 
Here we describe an exercise in which we sought to improve the quality of animal cardiac and 73 
metabolic studies at a research institute in Australia. The exercise consisted of: i) a short survey to 74 
acquire baseline data on current practices regarding the conduct of animal studies; ii) a series of 75 
presentations for promoting awareness, and providing advice and practical tools for improving 76 
experimental design; and iii) a follow-up survey 12 months later to assess whether practices had 77 
changed. Throughout the process, investigators were assured that this was not an exercise with 78 
repercussions on performance, but rather a process to obtain honest answers from investigators to 79 
understand any barriers/challenges hindering laboratories from undertaking more formal 80 
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procedures for reducing bias. It was emphasized that honest answers would provide an opportunity 81 
to identify solutions for improving the quality of preclinical animal research. 82 
 83 
Materials and Methods 84 
Study overview 85 
The Baker Heart and Diabetes Institute (Melbourne, Australia) undertook an exercise to evaluate 86 
and improve practices encompassing the performance of preclinical research. An overview of the 87 
entire process is presented in Table 1 and included 1) presentations, 2) two short surveys rolled 88 
out approximately 12 months apart, 3) practical tools for encouraging improved practices, and 4) 89 
follow-up from senior members of the Institute, i.e. laboratory visits from the Institute Director (Prof 90 
Thomas Marwick) and the Head of the Basic Science Domain/Division (A/Prof Julie McMullen). 91 
Surveys 92 
Two short surveys (designed to be completed in 10-12 min or less) were developed and delivered 93 
via an online form on the Institute intranet. The surveys were provided to research staff and 94 
graduate students undertaking animal research in June 2017 and June/July 2018.  95 
Inclusion criteria: The surveys were compulsory for responsible investigators from the Baker 96 
Institute with an active animal ethics application. A list of responsible investigators was provided by 97 
the Animal Ethics Officer (Alfred Health and Education Precinct Animal Ethics Committee). 98 
The 2017 survey collected baseline data on existing practices within the institute in respect to the 99 
conduct of animal studies, with a focus on experimental design (e.g. blinding, randomization and 100 
allocation concealment). The aim of the 2018 survey was to determine whether practices had 101 
improved over a period of 12 months. Questions from both surveys are presented within Source 102 
Data (Appendix I and II, available at https://figshare.com/s/1788601bf6606df6f5a5). 103 
In this paper, we present the responses to questions within the 2017 and 2018 surveys which were 104 
specifically related to: a) Pre-specified criteria for inclusions/exclusions; b) declaration of primary 105 
and secondary endpoints; c) sample size calculations; d) randomization of animals and method 106 
used; e) allocation concealment, de-identifying interventions, and blinding; and f) attitudes towards 107 
the quality and rigor of animal studies being undertaken. The main goal was to understand whether 108 
practices and behaviors had changed over a period of 12 months. 109 
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Pre-specified criteria for inclusions/exclusions. Within the research fields of cardiac biology, 110 
diabetes and obesity, it is not uncommon for investigators to exclude animals based on: i) 111 
unsuccessful cardiac surgery; ii) mice not becoming diabetic when administered streptozotocin 112 
(STZ) based on blood glucose levels; iii) inadequate weight gain on a high fat diet and/or skin 113 
lesions (prior to an intervention); iv) mice not weight-matched prior to an intervention assessing 114 
weight gain/metabolism. These criteria should be considered prior to experimentation and reported 115 
in publications. Depending on the study design, animals may be excluded: i) prior to entering a 116 
study e.g. a runt in a litter with a particularly low body weight that could not be weight-matched for 117 
a metabolic study; ii) after an intervention (e.g. cardiac surgery/STZ injection) but prior to a 118 
treatment e.g. due to surgical complication/low blood glucose not meeting the definition of 119 
diabetes; iii) after a treatment but prior to study endpoint due to animal welfare issues; or iv) after 120 
study endpoint once molecular analyses of tissue have been performed e.g. a study designed to 121 
assess gene therapy in the heart but transduction of the heart with gene therapy was 122 
unsuccessful/sub-optimal to test the hypothesis. To encourage investigators to track and report 123 
exclusions of animals in future work, investigators were asked if they would consider using a 124 
template/flowchart (an example was provided within the survey) which had been proposed by 125 
Drucker (18), and which he designated the Consolidated Standards of Animal Experiment 126 
ReporTing (CONSAERT) flow diagram. 127 
Primary and secondary endpoints. In clinical research and journals publishing results of clinical 128 
trials it is mandatory/compulsory to define and report primary endpoints, which should be finalized 129 
before study completion and data analysis. This is typically not a requirement for preclinical 130 
research, and reporting of this information has been far less common, particularly for discovery 131 
research. The purpose of incorporating questions related to defined endpoints was to encourage 132 
preclinical researchers to consider stating primary endpoints for interventional studies in future, 133 
e.g. testing of a drug or genetic intervention in a mouse disease model on a cardiac function 134 
parameter such as fractional shortening by echocardiography. This provides differentiation 135 
between more robust findings relating to primary outcomes and hypothesis-generating outcomes 136 
when the primary outcome is not proven. 137 
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Sample size calculations. Power calculations are routinely part of clinical, but not laboratory, 138 
research culture. Nonetheless, their use is important to minimize the risk of type 2 error, as well as 139 
ensuring the ethical use of animals.   140 
Randomization of animals and method used. The importance of a structured or systematic 141 
approach for randomization is well recognized in the clinic (55), and the need for randomization in 142 
animal studies has gained attention more recently (25). Within preclinical research, it is not 143 
uncommon for investigators to use unstructured methods or “haphazard selection” when assigning 144 
animals to different experimental groups (29). 145 
Allocation concealment, de-identifying interventions, and blinding. It is recognised that when 146 
researchers are aware of experimental groups and treatments, unconscious bias may result in 147 
researchers caring for animals differently, and subsequently in larger effect sizes (37, 53). The 148 
differences and importance of allocation concealment and blinding for animal studies have been 149 
well described on the NC3Rs Experimental Design Assistant website 150 
(https://eda.nc3rs.org.uk/experimental-design-blinding). “Allocation concealment refers to 151 
concealing the allocation sequence (the treatment to be allocated to each individual animal) from 152 
the people assigning the animals to intervention groups, until the moment of assignment. Together 153 
with randomization, allocation concealment helps minimise selection bias, which introduces 154 
systematic differences in the characteristics of animals allocated to treatment groups. Allocation 155 
concealment enables blinding; for adequate blinding, the allocation sequence should not be 156 
revealed to the people conducting the experiment until the data has been analysed”.  157 
A number of our preclinical researchers perform intervention studies in disease and/or genetic 158 
animal models (e.g. surgical for heart disease models, STZ-induced diabetes, high fat diet for 159 
obesity), with drugs, gene therapies (e.g. adeno-associated virus; AAV), and different dietary 160 
approaches. To gain further insight into what components of the experimental design were being 161 
concealed and blinded, and to determine the potential willingness of investigators to incorporate 162 
more formal strategies for allocation concealment, follow-up questions were asked. For example: 163 
“For drug/AAV/diet studies, are interventions labelled ‘A’ and ‘B’ or equivalent? If no, would you 164 
consider this for future studies?” 165 
 166 
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 167 
Presentations and tools 168 
One hour educational sessions were presented to animal users throughout the exercise as outlined 169 
in Table 1. Sessions were delivered by the Domain Head of Basic Science and senior researchers 170 
(Dr Kate Weeks and Dr Darren Henstridge) who were actively conducting animal studies.  171 
Flow charts/templates were provided to investigators based and adapted from the CONSAERT 172 
flow chart proposed by Drucker (18); see Source Data (Appendix III available at 173 
https://figshare.com/s/1788601bf6606df6f5a5). 174 
 175 
Data collection 176 
The surveys were provided via a web interface on the institute’s intranet. Correspondence about 177 
the 2017 survey and the importance and rationale for conducting the survey was sent to all 178 
research staff and students via email from the Institute Director. Research staff listed as the 179 
responsible investigator on at least one active animal ethics application were informed that the 180 
survey was compulsory and received a follow-up email from the Head of the Basic Science 181 
Domain. To encourage investigators to respond openly and without reservations, examples of 182 
responses from the Head of the Basic Science Domain’s laboratory were provided to highlight that 183 
the goal was to obtain honest responses, not ‘perfect’ responses. The 2018 survey was 184 
compulsory for all responsible investigators who completed the survey in 2017. Paired responses 185 
from 6 responsible investigators could not be obtained (2 overseas during at least 1 survey, 3 186 
investigators leaving the institute in 2018, 1 non-responder). Other scientists undertaking animal 187 
research were encouraged to complete the survey. Two reminder emails were sent by the Head of 188 
the Basic Science Domain.  189 
Data from both surveys were exported into Excel and the collated results graphed in GraphPad 190 
Prism 7.03. The data for the responsible investigators are presented as bar graphs and line graphs 191 
to demonstrate how practices of individuals changed. The raw data were checked by more than 192 
one author to ensure reliability. 193 
 194 
 195 
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 196 
Statistics 197 
The two areas in which changes in practice were considered most likely to occur within 12 months 198 
were: 1) the uptake of using a structured method for randomization; and 2) de-identifying 199 
drugs/treatments by labelling them “A” and “B” or an equivalent. The Wilcoxon Sign-Rank Test for 200 
paired data was performed on the paired data (before and after) for these primary outcomes with a 201 
type I error set at 5%. The method of Agresti and Min (1) was used to calculate the proportion of 202 
investigators showing improved practices. This method takes into consideration bias when sample 203 
size is small (1).  Other outcomes were not subjected to statistical testing, because of the 204 
combination of small sample size and to avoid the risk of increasing type 1 error due to multiplicity 205 
of outcomes. Those results should therefore be seen only as hypothesis generating. 206 
 207 
Results 208 
Study population  209 
In total, 36 investigators completed the animal user survey in 2017 and 37 investigators completed 210 
the survey in 2018. The main analysis presents paired results from the 16 researchers listed as 211 
responsible/lead investigators on animal ethics applications. This included eight PIs/Lab Heads 212 
and eight Group Leaders/Research Officers. The results from all investigators (36 in 2017, 37 in 213 
2018) were comparable with the findings from the 16 responsible investigators (see Data 214 
Supplement for results from all investigators: available at 215 
https://figshare.com/s/7d252ccaa26110170985).   216 
All investigators were undertaking studies with genetic mouse models and/or mouse studies 217 
involving interventions e.g. drugs, gene therapy, diet interventions. 218 
 219 
Pre-specified criteria for inclusions/exclusions of animals 220 
In 2017, only 5 out of 16 responsible investigators were using pre-specified criteria for inclusions or 221 
exclusions of animals (e.g. unsuccessful cardiac surgery, mice not diabetic based on blood 222 
glucose levels) in 100% of their experiments (Fig 1A). In 2018, 9 out of 16 investigators reported 223 
using pre-specified criteria in all experiments, with the remaining 7 investigators reporting such use 224 
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in at least 50% of experiments (Fig 1A). Investigators were also asked whether pre-specified 225 
criteria were reported in publications and how often excluded animals were reported in 226 
publications. For both questions there was a spread of responses and no clear positive change 227 
over the 12 month period (Fig 1B and C). The most common reason for not including pre-specified 228 
criteria in publications was because this was not a requirement of journals. This also appeared to 229 
explain why some investigators reported pre-specified criteria and excluded animals in publications 230 
in 2017 but not 2018 i.e. this was the requirement of a journal when submitting in 2017 but not the 231 
requirement of another journal when submitting in 2018. One investigator provided answers of 232 
100% in 2017 and 0% in 2018 (Fig 1B and C). In this case, the investigator had not published an 233 
animal study during the 12 month period. The inclusion criterion for responsible investigators to 234 
participate in the survey was to be listed as the responsible investigator on an active animal ethics 235 
application. There was not a requirement to publish a paper over the 12 month interval. The 236 
response from this one investigator (illustrated by a dotted line, Fig 1B and C) highlights a limitation 237 
of the survey questions. In this case, the reported measure of 0% provided by the investigator does 238 
not represent 0%. Future surveys should allow for a response of “Not applicable” and include a 239 
follow-up question to explain why “Not applicable” was selected. It should be noted that all other 240 
investigators who reported 0% had published papers over the 12 month period. 241 
An example of a flowchart template was provided to assist and encourage researchers to track and 242 
report exclusions of animals (Fig 2A, modified version of CONSAERT (18)). In 2017, the majority of 243 
responsible investigators indicated they would use the template (Fig 2B). In 2018, 7 of 16 244 
responsible investigators had begun using the template (Fig 2C). Reasons provided for not using 245 
the template included: i) new studies had not yet begun but the templates will be used for new 246 
animal studies; ii) the laboratory had created other templates or spreadsheets. 247 
 248 
Primary and secondary endpoints 249 
The number of responsible investigators using primary and secondary endpoints 100% of the time 250 
(i.e. having a key parameter for judging study outcome e.g. a change in cardiac function by 251 
echocardiography) increased over the 12 month period from 6 to 11 of 16 (Fig 3A). There may be 252 
situations (e.g. exploratory studies) in which primary endpoints and outcomes are specified after 253 
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the study is underway. However, a similar trend was observed for investigators specifying 254 
endpoints prior to commencement of experimentation (Fig 3B). There was minimal change in the 255 
number of investigators stating pre-specified endpoints in publications (Fig 3C). Reasons for not 256 
stating specific endpoints included: 1) journals had not requested this information; 2) for discovery 257 
research it is uncertain what parameters/endpoints might change, so there are multiple endpoints 258 
(i.e. exploratory endpoints; N.B. potential driver for false positive results given 1:20 endpoints 259 
would be positive by chance; conditional on the null hypothesis being true); 3) for new studies it 260 
can be difficult to predict effect sizes.  A number of investigators noted they were planning to 261 
include this information in future publications, but they had not published any new studies since the 262 
recommendations were made in 2017. Two investigators indicated that pre-specified endpoints 263 
were reported in publications 100% of the time in 2017 but 0% in 2018 (Fig 3C). One investigator 264 
had not published an animal study during the 12 month period (response illustrated by a dotted 265 
line). The other investigator published in journals in which this information was not requested. 266 
 267 
Sample size calculations 268 
In 2017, 9 of 16 investigators were using power calculations 100% of the time to determine sample 269 
size. This increased to 11 of 16 investigators in 2018 (Fig 4). Though, of note, some of the 270 
investigators who indicated they were using power calculations 100% of the time in the 2017 271 
survey, were performing power calculations only 50% or 75% of the time in 2018. The most 272 
common reason investigators gave for not using a power calculation was that basic science 273 
studies are often exploratory in nature. A pilot study is often required before effect sizes and 274 
variability in the measure of a parameter can be determined. 275 
 276 
Randomization of animals and method used 277 
In the 2017 survey, the majority of investigators claimed to be randomizing mice to a specific 278 
treatment or intervention (Fig 5A). However, upon asking what method of randomization was being 279 
used in a follow-up question, it became apparent that all of the 16 responsible investigators were 280 
using no structured method for randomization (Fig 5B, white bar).  Within the 2017 survey we 281 
further asked: “If you are using “no structured method” for randomization, would you consider using 282 
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a structured method?”. The majority of investigators (15 of 16) responded “yes” to this question. 283 
Given that there is the potential for bias to influence the allocation of animals into a specific group, 284 
information sessions to describe the pitfalls of not using a structured method were delivered to 285 
researchers, together with tools for performing randomization using computer-based methods e.g. 286 
NC3Rs Experimental Design Assistant, GraphPad QuickCalcs, RAND function in Excel; see 287 
Source Data (Appendix IV available at https://figshare.com/s/1788601bf6606df6f5a5). The uptake 288 
of a formal method for randomization was an area in which we considered changes in practice 289 
could occur relatively quickly (i.e. within 12 months) because it was a strategy which was relatively 290 
quick and easy. In 2018, all 16 responsible investigators were randomizing mice to a 291 
treatment/intervention 100% of the time (Fig 5A). Half of the investigators were using a computer-292 
generated method or blind sealed envelope/other structured method (pulling numbers out of a hat) 293 
in 2018 (Fig 5B). The proportion of investigators demonstrating an improved practice (i.e. going 294 
from an unstructured method to structured: computer-generated/sealed envelope/numbers from a 295 
hat) was estimated to be 0.44 (95% CI: 0.19; 0.70; P=0.003). For the other half of investigators still 296 
randomizing mice with no structured method, reasons for this were requested. For most 297 
investigators, it was noted that studies/experiments had begun prior to the information session on 298 
new tools, and that for upcoming studies a structured method would be used. In some cases there 299 
were misconceptions about difficulties randomizing mice from small batches and study designs 300 
requiring mice to be body weight matched. In a follow-up session, examples of how structured 301 
randomization could be used in these situations were provided, e.g.  stratified randomization for 302 
body weight matching (see Source Data, Appendix IV available at 303 
https://figshare.com/s/1788601bf6606df6f5a5). 304 
 305 
Allocation concealment, de-identifying interventions, and blinding 306 
Allocation concealment: The purpose of the first survey question was to assess the overall 307 
potential of performance bias within a study e.g. investigators providing different degrees of care to 308 
animals based on treatment or genotype. In 2017, the majority of investigators (13 of 16) indicated 309 
they were performing allocation concealment 50% or less of the time (Fig 6A). By contrast, in 2018, 310 
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the majority of investigators (11 of 16) were performing allocation concealment 50-100% of the 311 
time (Fig 6A).  312 
De-identifying interventions: Performance bias can be eliminated or reduced by labelling 313 
drugs/interventions ‘A’ and ‘B’ or an equivalent.  In 2017, most researchers were not blinded to the 314 
intervention assigned to an animal group (Fig 6B; 13 of 16; white bars). However, 15 of 16 315 
investigators indicated a willingness to consider de-identifying interventions or drugs in future 316 
studies.  Thus, this was another area in which significant improvements in practice were 317 
considered possible within a 12 month period. At the time of the 2018 survey, 50% of investigators 318 
were de-identifying interventions (Fig 6B, black bars). The proportion of responsible scientists 319 
showing an improved practice was 0.40 (95% CI: 0.12; 0.68; P=0.010). Researchers were also 320 
asked if they incorporated blinding into other components of their studies. In most cases this 321 
included blinding of measurements and analysis of tissues post-animal experimentation (e.g. 322 
molecular and histological analyses). All investigators incorporated blinding into some aspect of 323 
their studies in 2017 (Fig 6C; 25-100%). In 2018, 8 of 16 responsible investigators were including 324 
blinding 100% of the time (Fig 6C). Reported challenges associated with allocation concealment, 325 
de-identifying drugs/interventions, and blinding included: 326 
a) It can be difficult to conceal diets in diet intervention studies (e.g. high fat chow is a different 327 
color to standard chow). However, genotypes/treatments would still be blinded within these 328 
studies. If interventions are unable to be blinded, then animal identification numbers are 329 
reassigned at the conclusion of the study to ‘re-blind’ for analysis.   330 
b) Lack of personnel- In some studies, drugs need to be mixed with vehicle just prior to 331 
administration. Many labs only have one technician so the same technician will mix the 332 
drug followed by immediate delivery to the mice.  333 
c) Different monitoring/care requirements can be required for different interventions e.g. 334 
diabetic animals require extra/daily care and have to have additional labelling on cages; 335 
animals on a high fat diet require additional monitoring for skin lesions. 336 
Practical solutions were provided to researchers in an information session. Examples are provided 337 
in Table 2. 338 
 339 
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Quality and rigor of animal studies: Changes in attitudes, practices and uptake of tools 340 
In 2017, 15 of 16 responsible investigators indicated that the quality and rigor of their animal 341 
studies could be improved (Fig 7A). In the 2018 survey, respondents were asked whether they 342 
perceived an improvement in their animal studies over the past 12 months. Fifteen of 16 343 
investigators indicated that the quality and rigor of their animal studies had improved (Fig 7B), and 344 
13 of 16 indicated they had changed practices regarding randomization, blinding and/or animal 345 
reporting (Fig 7C). Participants were asked to provide specific examples. These included: using a 346 
structured method for randomization, additional blinding, allocation concealment (e.g. labelling 347 
drugs “A” and “B”), more sample size calculations, and providing additional information in 348 
publications. 349 
 350 
Discussion 351 
The primary goal of this exercise was to encourage preclinical researchers to improve the quality of 352 
their cardiac and metabolic animal studies by incorporating strategies and protocols for the 353 
removal or reduction of bias. This was achieved by: i) increasing awareness of concerns which can 354 
arise from experimental designs that do not incorporate measures to exclude/limit bias; ii) providing 355 
knowledge, tools and templates to overcome bias/promote accurate reporting; and iii) rolling out 356 
two short surveys approximately 12 months apart to monitor any changes in practice and behavior. 357 
The major findings to come from the exercise included: 1) a willingness of investigators to make 358 
change when provided with knowledge and tools/solutions which were relatively simple to 359 
implement; 2) resistance to change if this involved more personnel and time; and 3) evidence that 360 
changes to long term practices (“habits” acquired over years) require time, follow-up, and 361 
incentives/mandatory requirements. 362 
 363 
The most significant finding and change in practice identified by the survey was in regard to the 364 
randomization of animals. In 2017, most investigators were using unstructured methods for 365 
randomization. After highlighting the potential of unconscious bias to have an impact on the 366 
randomization process and providing information and tools for using formal methods, the number 367 
of people using a structured method in 2018 had increased to 50%. The options provided to 368 
 14
researchers included computer-generated approaches (highly encouraged: NC3Rs Experimental 369 
Design Assistant, GraphPad QuickCalcs, the RAND function in Excel), blind-sealed envelope, 370 
numbers from a hat, and flipping a coin or rolling a dice (though not encouraged: only suitable for 371 
large sample sizes). Uptake of these methods advanced relatively quickly and most investigators 372 
not currently using a structured method were planning to do so for future studies. 373 
 374 
In general, the majority of investigators were willing to change practices when provided with the 375 
relevant information and tools, and when changes were easy to implement. Strategies requiring 376 
more personnel, e.g. for allocation concealment, were more challenging, particularly for small 377 
laboratories, to adopt. It is recognised that clinical trials and animal studies with inadequate or 378 
inappropriate methods for allocation concealment can overestimate treatment effects (37, 53). 379 
Thus, it is important allocation concealment is encouraged. Within an information session it was 380 
highlighted that some smaller laboratories were managing the problem of limited staff for allocation 381 
concealment and blinding by involving personnel from other laboratories. This was viewed as a 382 
practical solution for laboratories that work well together, but can be more challenging for others.  383 
 384 
We and others have recognised that significant changes to experimental design and practices are 385 
likely to require monitoring, incentives and pressure from multiple groups, including journals, 386 
funding agencies, research institutes, universities, and animal ethics committees (3, 8, 13, 22, 23, 387 
27). It has been reported that while researchers may endorse or subscribe to practices or changes 388 
in behavior, this may not correlate with actual behaviors in practice (5). Granting agencies within 389 
Australia (e.g. National Health and Medical Research Council) and overseas (e.g. National 390 
Institutes of Health, Wellcome Trust) have recognized the concern (14) and are encouraging 391 
enhanced reproducibility by incorporating relevant elements of experimental design 392 
(randomization, allocation concealment, blinding) within the assessment criteria of research 393 
proposals (16). Our training sessions also highlighted the more stringent experimental design and 394 
reporting requirements of journals and granting agencies as an incentive to encourage change. 395 
However, a requirement for explicit reporting from journals of specific experimental design details 396 
(e.g. method of randomization, de-identification of drugs) is likely to be necessary to drive 397 
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significant changes in practice. In undertaking a general review of recent publications from Am J 398 
Physiology- Heart and Circulation Physiology (using the search term “random”; Sept 2018-May 399 
2019), a number of investigators noted that animals had been randomized (12, 20, 21, 26, 30, 38, 400 
40, 41, 43, 50, 51, 54, 58). However, in the majority of cases, the method of randomization was not 401 
specifically stated. The exception to this was some examples of studies in large animals and 402 
humans (2, 31, 47, 49, 52). In these studies, structured methods of randomization had been 403 
included (e.g. computer-generated, random number table, stratified block randomization). 404 
 405 
Within our exercise, follow-up and monitoring progress after and between surveys was considered 406 
very important. This consisted of information sessions, distribution of relatively simple tools (e.g. for 407 
randomization and tracking animal exclusions), and laboratory visits from the Institute Director and 408 
Domain Head of Basic Science. The online provision of tools, templates, and guidelines for many 409 
aspects of preclinical research is becoming increasingly common and considered a valuable 410 
resource. Many journals including Am J Physiol Heart Circ Physiol have been leading the way in 411 
providing guidelines, e.g. on data visualization, reporting statistics, experimental animal models of 412 
cardiac disease, measuring cardiac physiology in mice, formalized training for subjective measures 413 
including echocardiography, validation and correct use of reagents e.g. antibodies (11, 15, 17, 22, 414 
24, 32-34, 56, 57).  415 
 416 
Providing a balanced perspective on the concerns of irreproducible research was considered 417 
another key aspect of this exercise. As highlighted by others in editorials and reviews, discovery 418 
science is exploratory in nature (22). For such research, pre-specifying endpoints is not always 419 
possible, and tentative conclusions can still be beneficial to the scientific community and lead to 420 
important follow-up studies (22). Throughout the process, we were transparent about the potential 421 
deterrents of more rigid experimental designs, but also highlighted the benefits (Table 3). One 422 
issue is the acknowledgement that carefully conducted studies typically produce smaller effect 423 
sizes on average (4, 37). Although these smaller effect sizes are more accurate, they can make 424 
papers more difficult to publish in high impact journals because of the bias towards "breakthrough" 425 
and “exciting” results. Paradoxically, investigators who pursue this more careful approach could be 426 
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out-competed by less thorough resarchers who win more funding on the back of their high impact 427 
(but sometimes less rigorous) publications. Though, of note, many high impact journals are now 428 
ensuring authors meet more rigorous checklists. Regardless, widespread and significant changes 429 
in practice are likely to require funders being made aware of the need to reward research quality 430 
regardless of the study outcomes. 431 
 432 
Limitations of the study: This was a self-reported study which makes verification of data 433 
challenging. To check whether practices had indeed changed or were changing, the Institute 434 
Director and Domain Head of Basic Science visited laboratories during and after the exercise. In 435 
some cases, responses could also be verified by independently checking publications from the 436 
laboratory before 2017 and after 2018, e.g. use of animal templates, reporting of animal exclusions 437 
(10, 39, 46). However, in other cases this was not possible because the period of time between 438 
initial manuscript submission and acceptance/publication can often exceed 12 months. The 439 
scenario of an investigator not publishing an animal study over 12 months had not been 440 
considered. In future, an additional option of “Not applicable” should be available for selection.  441 
Another limitation is that this was a single site study with a relatively small cohort of responsible 442 
investigators. Whether this same exercise rolled out in an environment with larger numbers of 443 
animal users (larger institutes and universities) would identify changes in practice is currently 444 
unclear.  445 
 446 
Future directions: When rolling out an exercise to improve practices and culture, it is important not 447 
to lose momentum, to reinforce desired practices among early adopters of change, and to promote 448 
change to more reluctant investigators.  This could be achieved by a number of means: 449 
a) Repeating the survey in future years to monitor the long term effects 450 
b) Incorporating additional aspects of design and reproducibility into Institutional Animal Care and 451 
Use Committee (IACUC)/Animal ethics committee (AEC) applications, i.e. if defined randomization 452 
protocols and blinded treatments become a requirement in animal protocols, it is likely to 453 
accelerate implementation of better practices for improvement of better animal study design and 454 
reporting. 455 
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c) Inducting new staff/students on aspects of good experimental design and practice so they are 456 
indoctrinated into that culture from the start.  457 
 458 
Summary: The approach we undertook to encourage improvements in preclinical cardiac and 459 
metabolic animal research included: 1) making researchers aware of the concerns; 2) providing 460 
knowledge, tools, skills and training to address the concerns; and 3) follow-up to monitor and 461 
encourage changed practices. This exercise resulted in changed attitudes, practices, and 462 
reporting. However, further improvements are needed and this will require continued follow-up, 463 
monitoring, and incentives. 464 
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Endnote 484 
At the request of the author(s), readers are herein alerted to the fact that additional materials 485 
related to this manuscript may be found at [https://figshare.com/s/1788601bf6606df6f5a5]. These 486 
materials are not a part of this manuscript and have not undergone peer review by the American 487 
Physiological Society (APS). APS and the journal editors take no responsibility for these materials, 488 
for the website address, or for any links to or from it. 489 
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Legends 669 
Figure 1. A: Responses from responsible investigators to a survey question related to 670 
incorporation of pre-specified criteria for inclusions/exclusions of animals within experimental 671 
designs from the original survey (2017) and follow-up survey (2018). B: Reporting of pre-specified 672 
criteria in publications. C: Reporting of excluded animals in publications. Right panels: lines were 673 
manually off-set within a band of responses (e.g. 0, 25, 50, 75, 100%) for easier visualization of 674 
individual responses (N=16). Dotted lines illustrate the responses from an investigator who did not 675 
publish a paper over the 12 month period. In this case, the reported measure of 0% provided by 676 
the investigator does not represent 0%. 677 
 678 
Figure 2. Responses from responsible investigators (N=16) regarding a willingness to use a formal 679 
procedure/flow chart to track animal exclusions. A: Example of a flowchart/template to track 680 
animals. B: Willingness of investigators to track animals with a flowchart/template. C: Uptake of 681 
using the template over a 12 month period. N.B. In panel B one investigator provided no response.  682 
 683 
Figure 3. A and B: Responses from responsible investigators (N=16) to survey questions related 684 
to pre-specified primary and secondary endpoints from the original survey (2017) and follow-up 685 
survey (2018). C: Reporting pre-specified endpoints/outcomes in publications. Right panels: lines 686 
were manually off-set within a band of responses (e.g. 0, 25, 50, 75, 100%) for easier visualization 687 
of individual responses (N=16). The dotted line illustrates the response from an investigator who 688 
did not publish a paper over the 12 month period. In this case, the reported measure of 0% 689 
provided by the investigator does not represent 0%. 690 
 691 
 692 
Figure 4. Responses from responsible investigators (N=16) to a survey question related to sample 693 
size calculations from the original survey (2017) and follow-up survey (2018). Right panel: lines 694 
were manually off-set within a band of responses (e.g. 0, 25, 50, 75, 100%) for easier visualization 695 
of individual responses (N=16). 696 
 697 
 698 
Figure 5. A and B: Responses from responsible investigators (N=16) to survey questions related 699 
to randomization of animals and the method of randomization used from the original survey (2017) 700 
and follow-up survey (2018). A: Right panel; lines were manually off-set within a band of 701 
responses (e.g. 0, 25, 50, 75, 100%) for easier visualization of individual responses (N=16). For 702 
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Fig 5B; P=0.005, Wilcoxon Sign-Rank Test when comparing a structured (desirable) method 703 
[computer-generated/sealed envelope/numbers from a hat] with an unstructured (undesirable) 704 
method. 705 
 706 
Figure 6. A-C: Responses from responsible investigators (N=16) to survey questions related to 707 
allocation concealment and blinding from the original survey (2017) and follow-up survey (2018).  708 
Panel A assessed responses to allocation concealment in regard to genotype or treatment. Panel 709 
B refers to intervention studies in which a test drug, gene therapy (e.g. adeno-associated virus, 710 
AAV) or modified diet (e.g. high fat diet) is administered to mice, and whether these interventions 711 
are blinded by labelling one intervention “A” and one “B” or some equivalent. Panel C refers to 712 
blinding post-animal experimentation. For panel 6B, P=0.010, Wilcoxon Sign-Rank Test; 713 
comparison of 2017 with 2018. Right panels: lines were manually off-set within a band of 714 
responses (e.g. 0, 25, 50, 75, 100%) for easier visualization of individual responses (N=16). 715 
 716 
Figure 7. A-C: Responses from responsible investigators (N=16) to survey questions related to 717 
their perception and practices in regard to the quality and rigor of animal studies from the original 718 
survey (2017, panel A) and follow-up survey (2018, panels B and C). 719 
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 734 
Table 1- Overview of exercise to improve the quality of preclinical animal research 735 
Activity Description 
Presentation- 
Background and 
awareness (mid-
April, 2017). One 
hour session 
including questions 
and discussion. 
-Concerns regarding the quality of animal research 
-ARRIVE Guidelines 
-Types of bias 
-Practical examples and considerations when blinding 
-Feedback and consultation 
Presentation- 
External speaker 
(late-April, 2017). 
Seminar: Improving disease modeling and candidate drug 
evaluation 
Survey preparation 
and testing (May 
2017). 
-Survey to assess baseline practices (May 2017) 
-Consultation on survey design and implementation  
-Trial testing of the survey with a scientist undertaking animal 
studies 
Survey rollout (June 
2017). 
Designed to be 
completed within 10-
12 min. 
 
-Email from Institute Director with instructions to complete the 
survey by week’s end. 
-Emphasis on acquiring honest responses to understand obstacles 
and barriers; example response provided from Head of Basic 
Science Domain to highlight we were looking for honest responses 
-Follow-up reminders during the week 
Communication of 
survey results (July 
2017). 
-A summary of the survey results and next steps was 
communicated to Science Faculty at a meeting July 21, 2017 
-A report of the survey results was distributed to Lab Heads and 
Scientists by email July 23, 2017 
-It was noted that animal templates and practical tools would be 
made available to researchers over the coming months 
Presentation- 
Survey results and 
practical tools (Sept 
2017). 
-Areas for improvement 
-Methods for randomization 
-Flow charts for tracking animals and exclusions 
Follow-up (March 
2018 to present). 
Institute Director and Head of Basic Science Domain visit labs on a 
monthly basis to:  
1) Assess uptake of new tools 
2) Identify potential issues/concerns 
Follow-up survey-
June 2018. 
-Email from Head of Basic Science Domain with instructions to 
complete a short compulsory follow-up survey within a week 
(expected to take 6-8 min). The survey was sent to an investigator 
to trial before sending it to all investigators. 
-Re-emphasis- acquiring honest responses to understand 
obstacles and barriers 
-Follow-up reminders during the week 
Communication and 
presentation of 
survey results-Sept 
2018. 
-A summary of survey results in 2018 compared to 2017 
-A reminder about randomization tools and flow charts 
-Example of inserting information into publications 
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 740 
Table 2- Challenges and solutions for reducing bias 741 
Challenges Solutions 
Diabetic and non-diabetic animals look 
physically different, e.g. diabetic mice have 
unkempt coats and require daily cage 
changes due to increased urination. 
Re-blind collected tissues/samples at study 
end. 
Drugs administered via a syringe are 
different in colour to the vehicle/control. 
Wrap the syringes in foil. 
Dietary intervention (e.g. high fat diet) is 
different in colour to the chow diet.  
Re-blind collected tissues/samples at study 
end. In some cases, it is possible to request 
the supplier to make the intervention and 
chow/control diet a different colour. 
Lack of personnel to label drugs “A” and “B” 
or to have different staff members blinding 
different analyses. 
Assistance from personnel in other 
laboratories.  
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 765 
Table 3. Implications of the introduction of more structured randomization & blinding 766 
 767 
Potential deterrents Benefits 
Increased time planning studies. Improved quality of research. 
Effect sizes are likely to be smaller. This may 
require larger animal numbers.  
Less dramatic results? 
Negative results from well designed studies 
are more likely to be published in good 
journals than negative results from poorly 
designed studies. 
More staff required for ensuring studies are 
blinded. 
 Fewer researchers following up on dead ends. 
Additional costs associated with more animals 
and lab staff time. 
More money, researchers time directed into 
research and targets which have the greatest 
opportunity for success. New drugs for 
patients. 
Fewer positive results. Lower risk of translational failure. 
Potential implications for high impact factor 
papers, productivity & career progression (with 
current reward structures) 
Less negative press. Greater confidence from 
the media and public.  
More philanthropic support. 
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